Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Rises By 194.3%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large increase in short interest during the month of February. As of February 13th, there was short interest totaling 226,049 shares, an increase of 194.3% from the January 29th total of 76,808 shares. Currently, 0.4% of the company’s shares are sold short. Based on an average daily volume of 258,111 shares, the days-to-cover ratio is presently 0.9 days. Based on an average daily volume of 258,111 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.4% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Guggenheim boosted their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Saturday, November 1st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.00.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH opened at $4.50 on Friday. The stock has a market capitalization of $304.11 million, a PE ratio of -9.78 and a beta of 1.11. SOPHiA GENETICS has a 52 week low of $2.58 and a 52 week high of $5.70. The stock’s 50-day moving average price is $4.93 and its 200-day moving average price is $4.40. The company has a quick ratio of 2.62, a current ratio of 2.80 and a debt-to-equity ratio of 0.78.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently added to or reduced their stakes in SOPH. Green Alpha Advisors LLC raised its position in SOPHiA GENETICS by 10.8% during the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after acquiring an additional 4,444 shares during the period. Dimensional Fund Advisors LP raised its position in shares of SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the last quarter. Savvy Advisors Inc. purchased a new position in SOPHiA GENETICS in the 3rd quarter valued at about $48,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS in the 3rd quarter worth about $49,000. Finally, Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the 4th quarter worth about $49,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.